The study, published July 6 in Science, used CRISPR Targeting to target extra chromosomes, known as aneuploidy, in melanoma, gastric cancer and ovarian cell lines. Researchers removed a long portion of chromosome 1, which is found in several cancers and linked to disease progression.
The study found aneuploidies play a role in cancer development and eliminating them stunts growth potential. Aneuploidy also causes “collateral therapeutic vulnerabilities that can be targeted to selectively eliminate cells with chromosome dosage imbalances,” researchers wrote.
At the Becker's Perioperative Summit, taking place October 29–31 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
